Life Sciences & Biotechnology
Title : | Antimicrobial Leads from Actinomycetes against some Clinical Pathogens in BRT Wildlife Sanctuary, Western Ghats: Evaluation and Characterization |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Microbiology |
Principal Investigator : | Dr. B V Thirumalesh, CSIR-Central Food Technological Research Institute, Telangana |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | thirubv@gmail.com |
Details
Executive Summary : | More than 3.8 million antimicrobial-resistant infections occur in world. and more than 70,000 people die as a result. The term “Antimicrobials” are the substances that are used to inhibit or kill the growth of pathogenic microorganisms. They play a pivotal role in treating and preventing various infectious diseases, in addition to saving patients' lives, antibiotics have been instrumental in achieving significant improvements in both surgery and medicine. The increasing global spread of resistant microbes threatens the effectiveness of antibiotics, which have revolutionized medicine and saved millions of lives. Several decades after the first patients received antibiotic treatment, bacterial infections are once more a danger. Antibiotics reduce food-borne illness and other poverty-related illnesses' morbidity and mortality in developing nations with still-poor sanitation. Natural products are naturally derived metabolites or by-products from microorganisms, plants, or animals, actinomycetes. Actinomycetes have been recognized natural products, as possible sources of bioactive secondary metabolites. Researches have proven that actinomycetes are potential sources of novel bioactive compounds for exploitation in modern medicine. Actinomycetes are a group of gram-positive bacteria that are well-known for their ability to produce a wide variety of bioactive compounds, including antimicrobial agents. Actinomycetes strains from the Western Ghats region of Karnataka will be isolated and studied along with earlier strains obtained from the same region in the present investigation. An emphasis will be given to the Streptomyces and Nocardia species from Chamarajanagara district of Karnataka forest areas. The selection of the strains will be done on the basis of initial screening dual assay method in vitro antagonism against human clinical pathogens. Single culture and Co-culture actinomycetes will be evaluated against clinical pathogens and also two or three potent actinomycetes co-inoculated into the broth and direct mixing refers to co-cultures grown in the same environment. The bioactive metabolites produced by selected organisms will be isolated, purified, and characterized through various analytical techniques. Both the crude as well as the purified compounds will be tested for their inhibitory properties against clinical pathogens and the promising compounds will be screened against emerging drug-resistant pathogens by WHO listed of urgent threat, concerning and serious threats. The synergistic effect of the isolated compounds along with clinically active antibiotics will be evaluated in pathogens. The promising compounds will be evaluated and their complete structural elucidation of the most promising lead molecule will be attempted through different analytical techniques. action of potent leads will be derived & industrial collaboration will be perceived for the development of potent, safe, and affordable clinical candidates against human pathogens. |
Total Budget (INR): | 40,00,924 |
Organizations involved